The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN1652253     (2S)-6-amino-N-[(2S)-2-[(2- amino-2-methyl...

Synonyms: DCL000850, DNC000230, AC1MI4W9, Anti-PrP antibodies
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ipamorelin

  • In +/lit and lit/lit mice ipamorelin induced a small (15%) increase in body weight by 2 weeks, that was not further augmented by 9 weeks [1].

High impact information on Ipamorelin

  • NNC 26-0235 demonstrated a 10% oral bioavailability in dogs, and NNC 26-0235 and ipamorelin were able to increase basal GH level by more than 10-fold after oral administration of a dose of 1.8 and 2.7 mg/kg, respectively [2].
  • This stomach-specific expression of ghrelin in seabream is subject to regulation, as administration of growth hormone or ipamorelin to the fish in vivo was demonstrated to enhance its expression [3].
  • Here we compared the effects of twice daily s.c. treatment of GH and the GHS, ipamorelin, on body fat in GH-deficient (lit/lit) and in GH-intact (+/lit and +/+) mice [1].
  • The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats [4].
  • CONCLUSIONS: The proposed PK/PD model provides a useful characterization of ipamorelin disposition and GH responses across a range of doses [5].

Biological context of Ipamorelin


Anatomical context of Ipamorelin


Associations of Ipamorelin with other chemical compounds

  • Very surprisingly, ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation [9].

Gene context of Ipamorelin


Analytical, diagnostic and therapeutic context of Ipamorelin


  1. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Lall, S., Tung, L.Y., Ohlsson, C., Jansson, J.O., Dickson, S.L. Biochem. Biophys. Res. Commun. (2001) [Pubmed]
  2. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. Ankersen, M., Johansen, N.L., Madsen, K., Hansen, B.S., Raun, K., Nielsen, K.K., Thogersen, H., Hansen, T.K., Peschke, B., Lau, J., Lundt, B.F., Andersen, P.H. J. Med. Chem. (1998) [Pubmed]
  3. Seabream ghrelin: cDNA cloning, genomic organization and promoter studies. Yeung, C.M., Chan, C.B., Woo, N.Y., Cheng, C.H. J. Endocrinol. (2006) [Pubmed]
  4. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Svensson, J., Lall, S., Dickson, S.L., Bengtsson, B.A., Rømer, J., Ahnfelt-Rønne, I., Ohlsson, C., Jansson, J.O. J. Endocrinol. (2000) [Pubmed]
  5. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Gobburu, J.V., Agersø, H., Jusko, W.J., Ynddal, L. Pharm. Res. (1999) [Pubmed]
  6. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Johansen, P.B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T.T., Wilken, M., Orskov, H. Growth Horm. IGF Res. (1999) [Pubmed]
  7. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Andersen, N.B., Malmlöf, K., Johansen, P.B., Andreassen, T.T., Ørtoft, G., Oxlund, H. Growth Horm. IGF Res. (2001) [Pubmed]
  8. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Adeghate, E., Ponery, A.S. Neuro Endocrinol. Lett. (2004) [Pubmed]
  9. Ipamorelin, the first selective growth hormone secretagogue. Raun, K., Hansen, B.S., Johansen, N.L., Thøgersen, H., Madsen, K., Ankersen, M., Andersen, P.H. Eur. J. Endocrinol. (1998) [Pubmed]
  10. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Jiménez-Reina, L., Cañete, R., de la Torre, M.J., Bernal, G. Histol. Histopathol. (2002) [Pubmed]
  11. Pharmacological characterisation of a new oral GH secretagogue, NN703. Hansen, B.S., Raun, K., Nielsen, K.K., Johansen, P.B., Hansen, T.K., Peschke, B., Lau, J., Andersen, P.H., Ankersen, M. Eur. J. Endocrinol. (1999) [Pubmed]
  12. Do growth hormone-releasing peptides act as ghrelin secretagogues? Ahnfelt-Rønne, I., Nowak, J., Olsen, U.B. Endocrine (2001) [Pubmed]
WikiGenes - Universities